For disseminated disease palliative chemotherapy regimens have included use of chemotherapy and immunotherapy agents such as dacarbazine (DTIC), ipilimumab (IPI), interferon-α, aldesleukin, and BRAF inhibitors such as vemurafenib (in patients with BRAF-mutated melanoma). This evidence concerns the gene IL2 and melanoma.